Citigroup Inc Ab Cellera Biologics Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Citigroup Inc holds 5,234 shares of ABCL stock, worth $15,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,234

Previous 79,289 93.4%

Holding current value

$15,440

Previous $234,000 94.44%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$2.39 - $3.49 $176,991 - $258,451	-74,055 Reduced 93.4%	5,234 $13,000
Q2 2024 Aug 12, 2024	BUY	$2.73 - $4.73 $205,429 - $355,927	75,249 Added 1862.6%	79,289 $234,000
Q1 2024 May 10, 2024	SELL	$4.29 - $5.97 $17,434 - $24,262	-4,064 Reduced 50.15%	4,040 $18,000
Q4 2023 Feb 09, 2024	BUY	$3.91 - $5.93 $15,022 - $22,783	3,842 Added 90.15%	8,104 $46,000
Q3 2023 Nov 09, 2023	SELL	$4.6 - $7.95 $17,291 - $29,884	-3,759 Reduced 46.86%	4,262 $19,000
Q2 2023 Aug 10, 2023	BUY	$5.66 - $7.59 $16,323 - $21,889	2,884 Added 56.14%	8,021 $51,000
Q1 2023 May 11, 2023	SELL	$7.31 - $11.18 $18,508 - $28,307	-2,532 Reduced 33.02%	5,137 $38,000
Q4 2022 Feb 09, 2023	SELL	$9.48 - $14.52 $22,837 - $34,978	-2,409 Reduced 23.9%	7,669 $77,000
Q3 2022 Nov 10, 2022	SELL	$9.2 - $13.68 $208,343 - $309,797	-22,646 Reduced 69.2%	10,078 $100,000
Q2 2022 Aug 10, 2022	BUY	$5.72 - $10.65 $124,135 - $231,126	21,702 Added 196.9%	32,724 $349,000
Q1 2022 May 12, 2022	SELL	$7.46 - $14.14 $16,628 - $31,518	-2,229 Reduced 16.82%	11,022 $107,000
Q4 2021 Feb 10, 2022	BUY	$12.99 - $17.73 $97,048 - $132,460	7,471 Added 129.26%	13,251 $189,000
Q3 2021 Nov 10, 2021	BUY	$14.85 - $21.34 $85,833 - $123,345	5,780 New	5,780 $116,000

Others Institutions Holding ABCL

# of Institutions

155

Shares Held

109M

Call Options Held

153K

Put Options Held

194K

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $841M
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account